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I In nt tr ro od du uc ct ti io on n
Stem cells receive broad attention in the scientific literature
and in society in general. This has been inspired by their
unique properties - the potential to self-renew and to
differentiate into multiple lineages. Human embryonic stem
cells (hESCs) have the ability to form all cells in the adult
body once they receive the proper signals. The capability to
control and direct differentiation in vitro would offer
opportunities to develop treatments for diseases that cannot
be treated today, especially in the area of regenerative
medicine, where the aim is to replace damaged tissue.
However, there are still many challenges before hESCs can
be safely used for clinical applications. Moreover, societal
and ethical issues need to be addressed before basic science
in this area could be successfully translated into the clinic.
The field of proteomics has matured immensely in recent
years, now allowing proteome biology investigation at
reasonable throughput in all areas of cell biology. Proteomics
researchers have started to chart the proteome of individual
primary stem cells and stem cell lines and their differentiated
derivatives, to define a subset of stem cell-specific proteins,
or to identify differentiation-specific proteins that can be
used as benchmarks for the intermediate or terminal steps of
stem cell differentiation. Importantly, proteomics studies
have shown that transcriptome analyses cannot fully explain
developmental changes, most likely because they are unable
to detect post-translational processes such as protein
modifications and protein-protein interactions.
At present, stem cell biology and proteomics are both rather
specialized scientific domains. Specialists from each field
seldom meet. Thus, crucial opportunities may be missed for
setting priorities and goals, and for maintaining consistent
and optimized standards for research where these fields
intersect, essential for an effective comparison of
experimental data across different laboratories. In response,
researchers from both fields have joined efforts in recent
years to facilitate joined meetings and initiate collaborative
research, resulting in a ‘Proteome Biology of Stem Cells’
initiative supported by both ‘parent’ organizations - the
Human Proteome Organization (HUPO) and the
International Society for Stem Cell Research (ISSCR). At the
‘parent’ meetings, specific parallel sessions are organized,
such as the ISSCR meeting in Barcelona (2009) and the
HUPO meeting in Amsterdam (2008).
Next to dedicated sessions/workshops at these meetings, it
was felt that a smaller get-together of specialists would
further enable researchers from both fields to bridge this gap
and derive optimal benefit from what each field has to offer.
On invitation by the European Bioinformatics Institute
(EBI) and the Wellcome Trust, the organizers aimed to bring
together specialists from both fields to discuss needs,
possibilities, requirements and conditions that will have to
be resolved before collaborative efforts can be successful.
The organizers were Rolf Apweiler (EBI, Hinxton), Mike
Dunn (UCD Conway Institute, Dublin, Ireland), Michael
Dunn (The Wellcome Trust, London, UK), Albert Heck(Utrecht University and Netherlands Proteomics Centre, The
Netherlands) and Richard Simpson (Ludwig Institute,
Melbourne, Australia). Throughout two days, approximately
100 participants from all over the globe gathered to present
and discuss recent results. Here, some of the presented
highlights are briefly summarized.
A At t   t th he e   c cr ro os ss sr ro oa ad ds s   o of f   s st te em m   c ce el ll ls s   a an nd d   p pr ro ot te eo om mi ic cs s
Alan Trounson (California Institute for Regenerative Medicine
(CIRM), San Francisco, USA) started the meeting by
providing an overview of research performed at CIRM. As its
director, Trounson gave warm support for proteomics in the
stem cell field by noting that ‘CIRM is committed to backing
research in stem cells and regenerative medicine and
recognizes the important role that proteomics will play in
the success of this new medicine’. Paul J Simons (University
of Texas, USA), former president of the ISSCR, focused on
the unique properties of adult stem cells and the challenges
faced by proteomics researchers when studying these cells.
In contrast to, for instance, embryonic stem cells (ESCs),
neural stem cells (NSCs) and mesenchymal stem cells
(MSCs), stem cells from adult tissues, cannot be easily
propagated in vitro and, therefore, the amount of cells that
can be analyzed is limited. He showed that the identification
of CD143 as a surface candidate marker for hematopoietic
stem cells (HSCs) from human embryonic, fetal and adult
hematopoietic tissues might, however, assist to enrich this
stem cell population with a higher efficiency. Christine
Mummery (Leiden University Medical Centre, The
Netherlands) provided an overview of how proteomics has
been intertwined in her stem cell research. Her laboratory
focuses largely on the generation of human embryonic
cardiomyocytes from hESCs, whereby proteomics was used
to uncover early cardiomyocyte markers. She also pointed at
the high potential of induced pluripotent cells (iPSs) derived
from individual patients for regenerative purposes. The use
of isobaric tags for relative protein quantification (iTRAQ)
was applied to the study of ESC differentiation by Anthony D
Whetton (University of Manchester, UK). In this multi-
plexed way, temporal changes in the proteome of differ-
entiating ESCs could be monitored. Relative quantification
of over 1,600 nuclear proteins, including many transcription
factors (for example, Oct4, Sox2), was achieved. Comparison
with mRNA-based assays, chromatin immunoprecipitation
analysis of histone acetylation and RNA polymerase II
binding during ESC development demonstrated only partial
correlations. For example, the Polycomb gene family
members were found to be regulated at the post-trans-
lational level, as were many members of the Nanog protein
interactome. Whetton concluded that ‘the analyses of stem
cell protein networks require protein level analyses’.
Mahendra Rao (LIFE Technologies and Buck Institute, CA,
USA) further discussed the overall poor correlation between
proteomic and genomic data, but he also felt that this still
largely reflects technical difficulties in completely mapping
the proteome space. In his view, protein expression analysis
using phosphoprotein antibodies, protoarrays or exami-
nation of specific families of proteins had so far resulted in
the greatest success, with high correlation with gene
expression datasets.
P Pr ro ot te ei in n   m ma ar rk ke er rs s   o of f   s st te em m   c ce el ll ls s
Martin F Pera (University of Southern California, USA)
discussed the complexity of stem cells due to their micro-
environment. hESC cultures are heterogeneous, consisting
of a spectrum of cells at various stages in a hierarchy of
developmental potential. These cells live in discrete
compartments within the culture, they communicate with
one another, and they can be identified by their expression
of extracellular matrix molecules, cell surface markers, and
growth factors. Pera concluded that the hESC micro-
environment is a fertile area for proteomics investigation, if
the technology can address the issues of limited sample size,
low abundant proteins, and complex post-translational
modifications. Albert Heck focused on the identification of
cardiomyocyte-specific cell surface markers by proteomics,
which may potentially be used for sorting purposes during
early stages of their in vitro propagation from hESCs.
Dedicated protocols to enrich membrane proteins,
applicable to minute amounts of stem cells, were discussed.
Putative markers could be distilled from a comparative
analysis of hESC-derived cardiomyocytes and cardiomyo-
cytes derived from fetal heart tissue, using stable isotopes of
amino acids in cell culture (SILAC) to label the hESCs. One
of the most recent breakthroughs in the field of stem cell
research has been the finding that cells may be re-
programmed to a pluripotent state (iPS) by bringing in a few
stem cell-specific transcription factors; c-Myc, Klf4, Oct4
and Sox2. Initially, low-efficient, plasmid-based delivery
methods and more efficient viral vectors were used, whereby
the latter pose a risk of uncontrollable insertional muta-
genesis with related tumor genesis risks. Andras Nagy
(Mount Sinai Hospital, Canada) showed a method to over-
come these issues, making use of the piggyBack transposon/
transposase system to deliver the reprogramming factors.
Interestingly, this method allows the removal of the
transposon insertions from established iPS cell lines,
providing a unique tool for high-throughput technologies
such as proteomics to investigate the molecular basis of the
cellular reprogramming process. Nagy could show that the
cells could be reprogrammed in a synchronous way.
S Si ig gn na al li in ng g   i in n   s st te em m   c ce el ll ls s
The mechanisms controlling the differentiation process of
ESCs are poorly understood. Using SILAC-based quantita-
tive mass spectrometry (MS), Jeroen Krijgsveld (University
of Utrecht, now at the European Molecular Biology
Laboratory (EMBL), Heidelberg, Germany) and Blagoy
Blagoev (University of Southern Denmark, Denmark)
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cells following induced differentiation. The results pre-
sented, covering several thousand phosphoproteins simul-
taneously, revealed several important changes in the
pluripotent core regulatory networks. Krijgsveld showed for
Sox2 a delicate interplay between SUMOylation and
phosphorylation, providing new insights into how hESCs
potentially exit the pluripotent state. From the work of both
Krijgsveld and Blagoev, the intricate cross-talk between
signaling pathways in stem cell differentiation became
clearly apparent.
S St te em m   c ce el ll ls s   a an nd d   d di is se ea as se e
Because of their potency, stem cells might be used as a
source of tissue replacement in regenerative medicine. How-
ever, many issues are nowadays faced by clinicians who
attempt to use pluripotent cells in practice. Andre Terzic
(The Mayo Clinic, MN, USA) discussed many of them and
showed some results of his research where proteomics and
other high-throughput technologies took a central role.
Different approaches were discussed, ranging from the use
of sorted cardiogenic progenitors from ESCs or autologous
reprogrammed iPSs to repair cardiac function in patients
with myocardial infarction. The stem cell niche, known as
the microenvironment in which stem cells are found and
that acts in regulating cell fate decisions, still remains largely
unexplored. Richard J Simpson (Ludwig Institute for Cancer
Research,  Melbourne, Australia) described proteomics
approaches that dealt with the secretome (secreted soluble
proteins), exosome (secreted membrane vesicles) and
peptidome (natural occurring peptides) during the epithelial-
mesenchymal transition.
C Co on nc cl lu ud di in ng g   r re em ma ar rk ks s
The meeting ended with a retreat in which researchers,
funding agencies (EU, Wellcome Trust, Genome Canada) and
publishers discussed several issues and opportunities, in the
perspective of cross-disciplinary research in this area. Small
in size, the meeting was a great success at initiating
discussions that will ultimately lead to more collaborative
efforts at the crossroads of stem cell and proteomics research.
A Ab bb br re ev vi ia at ti io on ns s
CIRM, California Institute for Regenerative Medicine; EBI,
European Bioinformatics Institute; EMBL, European
Molecular Biology Laboratory; ESC, embryonic stem cell;
hESC, human embryonic stem cell; HSC, hematopoietic
stem cell; HUPO, Human Proteome Organization; iPS,
induced pluripotent stem cell; ISSCR, International Society
for Stem Cell Research; iTRAQ, isobaric tags for relative
protein quantification; MS, mass spectrometry; MSC,
mesenchymal stem cell; NSC, neural stem cell; SILAC, stable
isotopes of amino acids in cell culture.
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